Bind Preps For Important Catalysts In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The nanomedicine developer said it expects to have results from two Phase II trials before the end of the year potentially validating its technology platform during its first year-end sales and earnings call since completing an IPO in September.